Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant GC versus dose-dense MVAC for muscle-invasive bladder urothelial carcinoma
2016-000658-37Phase 4Terminated
- Sponsor
- Medical University of Vienna
- Start
- Jun 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of gemcitabine, cisplatin, methotrexate, vinblastine and doxorubicin in transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Unacceptable toxicity. Started Jun 2016; status: terminated.
02
Drugs
gemcitabinecisplatinmethotrexatevinblastinedoxorubicin
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2016-000658-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000658-37.